Parallax Volatility Advisers
CTMX icon

Parallax Volatility Advisers’s CytomX Therapeutics CTMX Stock Holding History

Parallax Volatility Advisers’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-4,410
Closed -$93K – 2519
2017
Q4 		$93K Buy
+4,410
New +$91.4K ﹤0.01% 2850

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Parallax Volatility Advisers's CTMX Position: Q1 2018 in Review

Parallax Volatility Advisers sold out of CytomX Therapeutics (CTMX) in Q1 2018, closing a stake of 4,410 shares — an estimated $93K sold.

Parallax Volatility Advisers first reported a position in CTMX in Q4 2017 and held it in 1 quarter. The position peaked at $93K in Q4 2017. 141 funds tracked by Wall St. Rank hold CTMX as of Q1 2018.

  • Parallax Volatility Advisers reported no remaining CytomX Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 4,410 CytomX Therapeutics shares in Q1 2018, an estimated $93K.
  • Parallax Volatility Advisers first reported a position in CytomX Therapeutics in Q4 2017 and held it in 1 quarter.
  • Parallax Volatility Advisers's CytomX Therapeutics position peaked at $93K in Q4 2017.
  • 141 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2018.

Based on Parallax Volatility Advisers's 13F filing for Q1 2018, filed 15 May 2018.